U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369986) titled 'Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer' on Jan. 18.
Brief Summary: Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Immunotherapy
Mismatch Repair Deficiency
Intervention:
DRUG: Iparomlimab and Tuvonralimab (QL1706)
Iparomlimab and Tuvonralimab as a strategy to facilitate non-surgical management in women with surgically completely resectable dMMR endometrial cancer.
Recruitment Status: NOT_YET_RECRUITING
Spon...